Loading...

PerCP/Cyanine5.5 anti-mouse CD8a Antibody

Pricing & Availability
Clone
53-6.7 (See other available formats)
Regulatory Status
RUO
Other Names
T8, Lyt2, Ly-2
Isotype
Rat IgG2a, κ
Ave. Rating
Submit a Review
Product Citations
publications
53-6dot7_PerCPCyanine55_CD8a_Antibody_102318
C57BL/6 mouse splenocytes were stained with CD3ε FITC and CD8a (clone 53-6.7) PerCP/Cyanine5.5, or Rat IgG2a, κ PerCP/Cyanine5.5 isotype control (bottom).
  • 53-6dot7_PerCPCyanine55_CD8a_Antibody_102318
    C57BL/6 mouse splenocytes were stained with CD3ε FITC and CD8a (clone 53-6.7) PerCP/Cyanine5.5, or Rat IgG2a, κ PerCP/Cyanine5.5 isotype control (bottom).
Compare all formats See PerCP/Cyanine5.5 spectral data
Cat # Size Price Quantity Check Availability Save
100733 25 µg 70€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
100734 100 µg 190€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

CD8, also known as Lyt-2, Ly-2, or T8, consists of disulfide-linked α and β chains that form the α(CD8a)/β(CD8b) heterodimer and α/α homodimer. CD8a is a 34 kD protein that belongs to the immunoglobulin family. The CD8 α/β heterodimer is expressed on the surface of most thymocytes and a subset of mature TCR α/β T cells. CD8 expression on mature T cells is non-overlapping with CD4. The CD8 α/α homodimer is expressed on a subset of γ/δ TCR-bearing T cells, NK cells, intestinal intraepithelial lymphocytes, and lymphoid dendritic cells. CD8 is an antigen co-receptor on T cells that interacts with MHC class I on antigen-presenting cells or epithelial cells. CD8 promotes T cell activation through its association with the TCR complex and protein tyrosine kinase lck.

Product Details
Technical Data Sheet (pdf)

Product Details

Verified Reactivity
Mouse
Antibody Type
Monoclonal
Host Species
Rat
Immunogen
Mouse thymus or spleen
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation
The antibody was purified by affinity chromatography, and conjugated with PerCP/Cyanine5.5 under optimal conditions.
Concentration
0.2 mg/mL
Storage & Handling
The CD8a antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested
Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is < 1.0 µg per million cells in 100 µL volume. It is recommended that the reagent be titrated for optimal performance for each application.

* PerCP/Cyanine5.5 has a maximum absorption of 482 nm and a maximum emission of 690 nm.

Excitation Laser
Blue Laser (488 nm)
Green Laser (532 nm)/Yellow-Green Laser (561 nm)
Application Notes

Clone 53-6.7 antibody competes with clone 5H10-1 antibody for binding to thymocytes3. The 53-6.7 antibody has been reported to block antigen presentation via MHC class I and inhibit T cell responses to IL-2. This antibody has also been used for depletion of CD8a+ cells. Additional reported applications (for the relevant formats) include: immunoprecipitation1,3, in vivo and in vitro cell depletion2,10,15, inhibition of CD8 T cell proliferation3, blocking of cytotoxicity3,4, immunohistochemical staining5,6 of acetone-fixed frozen sections and zinc-fixed paraffin-embedded sections, and spatial biology (IBEX)29,30. Clone 53-6.7 is not recommended for immunohistochemistry of formalin-fixed paraffin sections. The Ultra-LEAF™ purified antibody (Endotoxin < 0.01 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for functional assays or in vivo studies (Cat No. 100746).

Additional Product Notes

BioLegend is in the process of converting the name PerCP/Cy5.5 to PerCP/Cyanine5.5. The dye molecule remains the same, so you should expect the same quality and performance from our PerCP/Cyanine5.5 products. Contact Technical Service if you have any questions.

Application References
  1. Ledbetter JA, et al. 1979. Immunol. Rev. 47:63. (IHC, IP)
  2. Hathcock KS. 1991. Current Protocols in Immunology. 3.4.1. (Deplete)
  3. Takahashi K, et al. 1992. P. Natl. Acad. Sci. USA 89:5557. (Block, IP)
  4. Ledbetter JA, et al. 1981. J. Exp. Med. 153:1503. (Block)
  5. Hata H, et al. 2004. J. Clin. Invest. 114:582. (IHC)
  6. Fan WY, et al. 2001. Exp. Biol. Med. 226:1045. (IHC)
  7. Shih FF, et al. 2006. J. Immunol. 176:3438. (FC)
  8. Kamimura D, et al. 2006. J. Immunol. 177:306.
  9. Bouwer HGA, et al. 2006. P. Natl. Acad. Sci. USA 103:5102. (FC, Deplete)
  10. Kao C, et al. 2005. Int. Immunol. 17:1607. PubMed
  11. Ko SY, et al. 2005. J. Immunol. 175:3309. (FC) PubMed
  12. Rasmussen JW, et al. 2006. Infect. Immun. 74:6590. PubMed
  13. Lee CH, et al. 2009. Clin. Cancer Res. PubMed
  14. Geiben-Lynn R, et al. 2008. Blood 112:4585. (Deplete) PubMed
  15. Kingeter LM, et al. 2008. J. Immunol. 181:6244. PubMed
  16. Guo Y, et al. 2008. Blood 112:480. PubMed
  17. Andrews DM, et al. 2008. J. Virol. 82:4931. PubMed
  18. Britschqui MR, et al. 2008. J. Immunol. 181:7681. PubMed
  19. Kenna TJ, et al. 2008. Blood 111:2091. PubMed
  20. Jordan JM, et al. 2008. Infect. Immun. 76:3717. PubMed
  21. Todd DJ, et al. 2009. J. Exp. Med. 206:2151. PubMed
  22. Bankoti J, et al. 2010. Toxicol. Sci. 115:422. (FC) PubMed
  23. Medyouf H, et al. 2010. Blood 115:1175. PubMed
  24. Riedl P, et al. 2009. J. Immunol. 183:370. PubMed
  25. Apte SH, et al. 2010. J. Immunol. 185:998. PubMed
  26. Bankoti J, et al. 2010. Toxicol. Sci. 115:422. (FC) PubMed
  27. del Rio ML, et al. 2011. Transpl. Int. 24:501. (FC) PubMed
  28. Cui L, et al. 2015. J Control Release. 206:220. PubMed
  29. Radtke AJ, et al. 2020. Proc Natl Acad Sci U S A. 117:33455-65. (SB) PubMed
  30. Radtke AJ, et al. 2022. Nat Protoc. 17:378-401. (SB) PubMed
Product Citations
  1. Schuster M, et al. 2017. J Immunol. 199:920. PubMed
  2. Yoon J et al. 2018. J Vis Exp. -141 . PubMed
  3. Turecamo SE, et al. 2018. Matrix Biol. 67:01:00. PubMed
  4. Garber C, et al. 2019. Nat Neurosci. 1.802777778. PubMed
  5. Wang X, et al. 2019. Cell Res. 29:787. PubMed
  6. Zheng X, et al. 2019. PLoS Pathog. 15:e1008036. PubMed
  7. Lang J, et al. 2020. Nat Commun. 11:1338. PubMed
  8. Hudson WH, et al. 2020. Immunity. 51(6):1043-1058.e4.. PubMed
  9. Zhang H, et al. 2021. Front Immunol. 12:644520. PubMed
  10. Vella JL, et al. 2021. Life Sci Alliance. 4:. PubMed
  11. Dai L, et al. 2020. Cell. 182(3):722-733.e11. PubMed
  12. Xing J, et al. 2021. Cell Reports. 35(12):109205. PubMed
  13. Zhou J, et al. 2019. Immunity. 50:403. PubMed
  14. Zhang R, et al. 2019. Cell Rep. 28:2647. PubMed
  15. Murata A, et al. 2020. Front Immunol. 11:775. PubMed
  16. Lefebvre MN, et al. 2021. Cell Rep. 37:109956. PubMed
  17. Kim D, et al. 2021. Nanomicro Lett. 13:31. PubMed
  18. Platt DJ, et al. 2021. Cell Reports. 35(6):109113. PubMed
  19. Gern BH, et al. 2021. Cell Host Microbe. 29(4):594-606.e6. PubMed
  20. Cornax I, et al. 2021. Microorganisms. 9:00. PubMed
  21. Barry KC, et al. 2018. Nat Med. 24:1178. PubMed
  22. Zhang P et al. 2019. Cell Rep. 27(11):3117-3123 . PubMed
  23. Kim CJ, et al. 2018. Immunity. 49:1034. PubMed
  24. Aldon Y, et al. 2020. J Immunol. 204:903. PubMed
  25. Van Den Eeckhout B, et al. 2020. NPJ Vaccines. 5:64. PubMed
  26. Yang C, et al. 2021. J Immunother Cancer. 9:. PubMed
  27. Sawada J, et al. 2021. Am J Pathol. 191:396. PubMed
  28. Chow MT et al. 2019. Immunity. 50(6):1498-1512 . PubMed
  29. Choi H et al. 2019. Cell Rep. 27(3):806-819 . PubMed
  30. Sultan H, et al. 2018. Cancer Immunol Res. 6:617. PubMed
  31. Yuzhu Hou et al. 2018. Immunity. 49(3):490-503 . PubMed
  32. Alotaibi F, et al. 2021. Front Immunol. 11:584937. PubMed
  33. Pack AD, et al. 2021. Cell Reports. 36:109586. PubMed
  34. Delacher M, et al. 2021. Immunity. 54(4):702-720.e17. PubMed
  35. Chen L, et al. 2020. Cancer Immunol Res. 0.457638889. PubMed
  36. Hayatsu N et al. 2017. Immunity. 47(2):268-283 . PubMed
  37. Wu J, et al. 2020. Sci Adv. 6:eaba3458. PubMed
  38. Hu D, et al. 2021. J Cell Mol Med. 25:2900. PubMed
  39. Juul-Madsen K, et al. 2021. Proc Natl Acad Sci U S A. 118:. PubMed
  40. Brooks JF, et al. 2020. Cytotherapy. 22:436. PubMed
  41. Kienzl M, et al. 2020. Oncoimmunology. 9:1776059. PubMed
  42. Hong JY, et al. 2020. Cell. 180(5):847-861. PubMed
  43. Xu X, et al. 2021. J Nanobiotechnology. 19:376. PubMed
  44. Sugita J, et al. 2021. Nat Commun. 12:1910. PubMed
  45. Paiva RS, et al. 2021. Eur J Immunol. 51:1968. PubMed
  46. Solanki A, et al. 2018. Development. 145. PubMed
  47. Stivala S, et al. 2019. J Clin Invest. 130:1596. PubMed
  48. Green DP, et al. 2019. Neuron. 101:412. PubMed
  49. Terashima Y, et al. 2020. Nat Commun. 11:609. PubMed
  50. Snyder LM, et al. 2022. Immunohorizons. 6:660. PubMed
  51. Mizraji* G, et al. 2013. J Vis Exp. 77: 50388. PubMed
  52. Collinson-Pautz M, et al. 2016. PLoS One. 11:e0164547. PubMed
  53. Dos Santos Dias L, et al. 2021. PLoS Pathog. e1009324:17. PubMed
  54. Chen X et al. 2017. Cell stem cell. 21(6):747-760 . PubMed
  55. Smith AS, et al. 2022. J Immunother Cancer. 10:. PubMed
  56. Agrawal M, et al. 2021. Cells. 10:. PubMed
  57. Yin Q, et al. 2021. Proc Natl Acad Sci U S A. 118: . PubMed
  58. Chen D, et al. 2020. Cancer Immunol Res. 8:883. PubMed
  59. Ruhland MK, et al. 2020. Cancer Cell. 37(6):786-799.e5. PubMed
  60. JI B, et al. 2016. Cell Death Differ. 23:759-75. PubMed
  61. Holvoet B, et al. 2015. Stem Cell Reports. 5: 1183-1195. PubMed
  62. Dekhtiarenko I, et al. 2013. J Immunol. 190:3399. PubMed
  63. Hönes J, et al. 2017. Sci Rep. . 10.1038/s41598-017-15866-9. PubMed
  64. Xu J et al. 2018. Cell. 173(3):762-775 . PubMed
  65. Kooreman NG et al. 2018. Cell stem cell. 22(4):501-513 . PubMed
  66. Ren J, et al. 2019. PLoS Biol. 17:e3000270. PubMed
  67. Hildebrand KM, et al. 2021. PLoS One. 16:e0253864. PubMed
  68. Shi R, et al. 2022. Theranostics. 12:875. PubMed
  69. Weaver JD, et al. 2022. Oncoimmunology. 11:2141007. PubMed
  70. Niknam S, et al. 2018. Clin Cancer Res. 24:5735. PubMed
  71. Novince CM, et al. 2017. Sci Rep. 7:5747. PubMed
  72. Place D, et al. 2017. PLoS One. 10.1371/journal.pone.0190384. PubMed
  73. Hu Y, et al. 2022. J Nanobiotechnology. 20:417. PubMed
  74. Fang E, et al. 2022. MedComm (2020). 3:e117. PubMed
  75. Tondini E, et al. 2022. NPJ Vaccines. 7:64. PubMed
  76. Brandi P, et al. 2022. Cell Rep. 38:110184. PubMed
  77. Chen X, et al. 2021. Cell Rep. 37:109991. PubMed
  78. Zuo W, et al. 2022. Cell Death Discov. 8:257. PubMed
  79. Zuo S, et al. 2021. J Immunother Cancer. 9:. PubMed
  80. Brigas HC, et al. 2021. Cell Reports. 36(9):109574. PubMed
  81. Barsoumian HB, et al. 2020. J Immunother Cancer. 8:00. PubMed
  82. Pilzecker B, et al. 2016. Nucleic Acids Res. 44: 4734 - 4744. PubMed
  83. Chung L et al. 2018. Cell host & microbe. 23(2):203-214 . PubMed
  84. Kemp V, et al. 2018. Cancer Gene Ther. 26:268. PubMed
  85. Wu J et al. 2019. Immunity. 50(5):1218-1231 . PubMed
  86. Kaur A, et al. 2019. Cancer Discov. 9:64. PubMed
  87. Liu W, et al. 2021. Cell Death Discov. 7:136. PubMed
  88. Carbone C, et al. 2021. J Immunother Cancer. 9:. PubMed
  89. Bourque J, et al. 2021. Heliyon. 7:e08311. PubMed
  90. Alameh MG, et al. 2021. Immunity. 54:2877. PubMed
  91. Bullard BL, et al. 2022. NPJ Vaccines. 7:65. PubMed
  92. Dutow P, et al. 2014. J Infect Dis. 209:1269. PubMed
  93. White C, et al. 2015. J Immunol. 194:697. PubMed
  94. Uddback I, et al. 2016. Sci Rep. 6:20137. PubMed
  95. Ying Zhang et al. 2017. Cancer cell. 32(3):377-391 . PubMed
  96. Karandikar SH, et al. 2019. Anal Chem. 91:3405. PubMed
  97. Sun Y, et al. 2022. Mol Ther Oncolytics. 25:160. PubMed
  98. Frost JN, et al. 2021. Med (N Y). 2:164. PubMed
  99. Ohtsuka J, et al. 2021. iScience. Online ahead of print. PubMed
  100. Maulloo CD, et al. 2021. Front Immunol. 12:714842. PubMed
  101. Zhao D, et al. 2020. Cancer Discov. 10:1374. PubMed
  102. Dobson HE, et al. 2020. Mucosal Immunol. 0.901388889. PubMed
  103. Parayath NN, et al. 2020. Nat Commun. 4.680555556. PubMed
  104. Lee L, et al. 2016. PLoS One. 11:e0167693. PubMed
  105. Wang Z et al. 2018. Immunity. 49(1):80-92 . PubMed
  106. Shi R, et al. 2019. J Cancer. 10:367. PubMed
  107. Karandikar SH, et al. 2019. JCI Insight. 5. PubMed
  108. Zhang W, et al. 2020. Nat Commun. 11:1187. PubMed
  109. Wuggenig P, et al. 2020. Commun Biol. 3:130. PubMed
  110. Yu H, et al. 2021. Front Oncol. 11:736882. PubMed
  111. Wüthrich M, et al. 2021. MBio. 12:e0201821. PubMed
  112. Ryan NM, et al. 2022. Front Immunol. 13:932742. PubMed
  113. Kohn EM, et al. 2022. J Immunol. 208:1417. PubMed
  114. Chandra J, et al. 2016. Immunol Cell Biol. 10.1038/icb.2016.83. PubMed
  115. Tang Y, et al. 2019. Nat Commun. 10:4157. PubMed
  116. Lee SC et al. 2018. Cancer cell. 34(2):225-241 . PubMed
  117. Matsumura T, et al. 2022. Nat Commun. 13:7064. PubMed
  118. Ghorbani S, et al. 2022. Nat Commun. 13:2445. PubMed
  119. Yuan M, et al. 2022. Oxid Med Cell Longev. 2022:5479491. PubMed
  120. Wang Y, et al. 2020. Virol Sin. 36:122. PubMed
  121. Desai P, et al. 2021. Cell. 184(5):1214-1231.e16. PubMed
  122. Dekhtiarenko I, et al. 2016. PLoS Pathog. 12:e1006072. PubMed
  123. Highton AJ, et al. 2019. Wellcome Open Res. 4:78. PubMed
  124. Liu YG, et al. 2019. FASEB J. 33:5018. PubMed
  125. Yao C, et al. 2018. Autophagy. 1.854861111. PubMed
  126. Li E, et al. 2021. Front Immunol. 12:667177. PubMed
  127. Mezzapelle R, et al. 2021. EMBO Mol Med. 13:e12344. PubMed
  128. Wang D, et al. 2022. EMBO Rep. 23:e53691. PubMed
  129. Unsinger J, et al. 2021. J Leukoc Biol. 109:697. PubMed
  130. Jing Y, et al. 2021. Front Immunol. 12:651860. PubMed
  131. Woodring T, et al. 2022. iScience. 25:104934. PubMed
  132. Pan Y, et al. 2021. Br J Pharmacol. 178:4907. PubMed
  133. Hartwig S, et al. 2014. PLoS One. 9:90720. PubMed
  134. Younes AI, et al. 2021. Transl Oncol. 14:100983. PubMed
  135. Muri J, et al. 2020. Cell Reports. 29(9):2731-2744.e4.. PubMed
  136. Schuster M, et al. 2019. Front Immunol. 10:1583. PubMed
  137. Bennion BG, et al. 2019. J Virol. 93. PubMed
  138. Contreras NA, et al. 2019. PLoS Pathog. 15:e1007890. PubMed
  139. Fan MY et al. 2018. Cell reports. 25(5):1204-1213 . PubMed
  140. Zhao N, et al. 2018. J Clin Invest. 26:84. PubMed
  141. Shaikh H, et al. 2021. Front Immunol. 12:689896. PubMed
  142. Okada R, et al. 2021. EBioMedicine. 67:103345. PubMed
  143. MaruYama T, et al. 2015. J Leukoc Biol. 98: 385-393. PubMed
  144. Borkner L, et al. 2017. J Immunol. 10.4049/jimmunol.1602115. PubMed
  145. Hendrikx S et al. 2019. Cell reports. 26(5):1227-1241 . PubMed
  146. Field CS, et al. 2020. Cell Metab. 31:422. PubMed
  147. Ireland L, et al. 2020. Front Immunol. 11:297. PubMed
  148. Van Den Eeckhout B, et al. 2020. NPJ Vaccines. 0.252777778. PubMed
  149. Cohen MA, et al. 2020. Cell Stem Cell. 26(4):579-592. PubMed
  150. Chao JL, et al. 2021. Cell Rep Med. 2:100399. PubMed
  151. Sun Y, et al. 2020. J Immunol. 205:2649. PubMed
  152. Zhang Z, et al. 2020. Nature. 579:415. PubMed
  153. Le QV, et al. 2022. Bioact Mater. 15:160. PubMed
  154. Xu Y, et al. 2016. Nat Commun. 7:12073. PubMed
  155. Yin X, et al. 2020. Cell Rep. 33:108278. PubMed
  156. Xu W, et al. 2021. Immunity. 54(3):526-541.e7. PubMed
  157. Sheppard S, et al. 2021. Cell Reports. 35(9):109210. PubMed
  158. Di Pilato M, et al. 2021. Cell. 184(17):4512-4530.e22. PubMed
  159. Kunishita Y, et al. 2020. Front Immunol. 11:98. PubMed
  160. Eckert EC, et al. 2020. Mol Ther Oncolytics. 0.710416667. PubMed
  161. Parks CA, et al. 2019. Proc Natl Acad Sci U S A. 116:3136. PubMed
  162. Säwen P et al. 2018. eLife. 7 pii: e41258. PubMed
  163. White JP et al. 2018. Cell. 175(5):1198-1212 . PubMed
  164. Sun Y, et al. 2022. iScience. 25:104846. PubMed
  165. Barsoumian HB, et al. 2022. Cancers (Basel). 14:. PubMed
  166. Teng F, et al. 2021. Cell Rep. 37:110051. PubMed
  167. Chen YL, et al. 2022. Front Neurosci. 16:876582. PubMed
  168. Wang J, et al. 2021. Am J Cancer Res. 11:2005. PubMed
  169. Kohn M, et al. 2021. Front Immunol. 626627:12. PubMed
  170. Guo X, et al. 2020. J Cell Mol Med. . PubMed
  171. Siolas D, et al. 2021. Cell Reports. 36:109578. PubMed
  172. Wan X, Thomas J, Unanue E 2016. J Exp Med. 213: 967 - 978. PubMed
  173. Li A, et al. 2018. Cancer Lett. 431:54. PubMed
  174. Caetano MS, et al. 2019. Clin Cancer Res. 25:7576. PubMed
  175. Hu Y, et al. 2021. J Nanobiotechnology. 19:416. PubMed
  176. RL M, et al. 2015. Proc Natl Acad Sci U S A. 112:6506-6514. PubMed
  177. Gorman M, et al. 2016. J Virol. 90: 8212 - 8225. PubMed
  178. Goc J, et al. 2021. Cell. 184:5015. PubMed
  179. Strattan E, et al. 2020. Frontiers in Immunology. 2.131944444. PubMed
  180. Wolf Y, et al. 2019. Cell. 179:219. PubMed
  181. Mohammed RN, et al. 2019. Sci Rep. 4.185416667. PubMed
  182. Tan DQ, et al. 2019. Cell Rep. 26:2316. PubMed
  183. Li CY, et al. 2022. Int J Mol Sci. 23:. PubMed
  184. Hodgson R, et al. 2022. Commun Biol. 5:1216. PubMed
  185. Chang MH, et al. 2021. Cell Rep. 37:109902. PubMed
  186. Dai B, et al. 2021. Cell Reports Medicine. 2(8):100381. PubMed
  187. Cortez MA, et al. 2020. Nat Commun. 3.819444444. PubMed
  188. Xiang W, et al. 2020. Signal Transduct Target Ther. 0.374305556. PubMed
  189. Harvey RE et al. 2017. Endocrinology. 158(7):2179-2189 . PubMed
RRID
AB_2075239 (BioLegend Cat. No. 100733)
AB_2075238 (BioLegend Cat. No. 100734)

Antigen Details

Structure
Ig superfamily, CD8α chain, 34 kD
Distribution

Most thymocytes, T cell subset, some NK cells, lymphoid dendritic cells

Function
Co-receptor for TCR
Ligand/Receptor
MHC class I molecule
Antigen References

1. Barclay A, et al. 1997. The Leukocyte Antigen FactsBook Academic Press.
2. Zamoyska R. 1994. Immunity 1:243.
3. Ellmeier W, et al. 1999. Annu. Rev. Immunol. 17:523.

Gene ID
12525 View all products for this Gene ID
UniProt
View information about CD8alpha on UniProt.org

Related FAQs

How stable is PerCP/Cyanine5.5 tandem as compared to PerCP alone?

PerCP/Cyanine5.5 is quite photostable and also better than PerCP alone in withstanding fixation.

Other Formats

View All CD8a Reagents Request Custom Conjugation
Description Clone Applications
APC anti-mouse CD8a 53-6.7 FC
Biotin anti-mouse CD8a 53-6.7 FC,IHC
FITC anti-mouse CD8a 53-6.7 FC
PE anti-mouse CD8a 53-6.7 FC
PE/Cyanine5 anti-mouse CD8a 53-6.7 FC
Purified anti-mouse CD8a 53-6.7 FC,CyTOF®,IHC-F,IP
PE/Cyanine7 anti-mouse CD8a 53-6.7 FC
APC/Cyanine7 anti-mouse CD8a 53-6.7 FC
Alexa Fluor® 488 anti-mouse CD8a 53-6.7 FC,3D IHC
Alexa Fluor® 647 anti-mouse CD8a 53-6.7 FC,IHC-F,3D IHC,SB
Pacific Blue™ anti-mouse CD8a 53-6.7 FC
Alexa Fluor® 700 anti-mouse CD8a 53-6.7 FC
PerCP/Cyanine5.5 anti-mouse CD8a 53-6.7 FC
PerCP anti-mouse CD8a 53-6.7 FC
Brilliant Violet 421™ anti-mouse CD8a 53-6.7 FC,IHC,SB
Brilliant Violet 570™ anti-mouse CD8a 53-6.7 FC
Brilliant Violet 650™ anti-mouse CD8a 53-6.7 FC
Brilliant Violet 605™ anti-mouse CD8a 53-6.7 FC
Ultra-LEAF™ Purified anti-mouse CD8a 53-6.7 FC,CyTOF®,IHC,IP,Depletion,Block
Brilliant Violet 711™ anti-mouse CD8a 53-6.7 FC
Brilliant Violet 785™ anti-mouse CD8a 53-6.7 FC
Brilliant Violet 510™ anti-mouse CD8a 53-6.7 FC
Purified anti-mouse CD8a (Maxpar® Ready) 53-6.7 FC,CyTOF®
Alexa Fluor® 594 anti-mouse CD8a 53-6.7 IHC-F,FC,3D IHC
PE/Dazzle™ 594 anti-mouse CD8a 53-6.7 FC
APC/Fire™ 750 anti-mouse CD8a 53-6.7 FC
GoInVivo™ Purified anti-mouse CD8a 53-6.7 FC
TotalSeq™-A0002 anti-mouse CD8a 53-6.7 PG
Spark Blue™ 550 anti-mouse CD8a 53-6.7 FC
Spark NIR™ 685 anti-mouse CD8a 53-6.7 FC
TotalSeq™-C0002 anti-mouse CD8a 53-6.7 PG
TotalSeq™-B0002 anti-mouse CD8a 53-6.7 PG
Spark YG™ 570 anti-mouse CD8a 53-6.7 IHC-F
PE/Fire™ 640 anti-mouse CD8a 53-6.7 FC
PE/Fire™ 700 anti-mouse CD8a 53-6.7 FC
Spark Blue™ 574 anti-mouse CD8a Antibody 53-6.7 FC
Spark Violet™ 423 anti-mouse CD8a Antibody 53-6.7 FC
Spark UV™ 387 anti-mouse CD8a 53-6.7 FC
Spark Blue™ 515 anti-mouse CD8a 53-6.7 FC
APC/Fire™ 810 anti-mouse CD8a 53-6.7 FC
Spark Red™ 718 anti-mouse CD8a (Flexi-Fluor™) 53-6.7 FC
Spark PLUS UV™ 395 anti-mouse CD8a 53-6.7 FC
Go To Top Version: 3    Revision Date: 10/23/2018

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

ProductsHere
Login / Register
Remember me
Forgot your password? Reset password?
Create an Account